Key facts
as of Sep 2026- It has raised $419.4M across 4 recorded rounds; the latest was Later Stage VC ($75.0M) in Feb 2025.
- Notable investors include Fidelity Management & Research Company, Valor Equity Partners, Fidelity, Paragon Biosciences, U.S. Food and Drug Administration.
- 2 institutional filers report fund marks on Castle Creek Biosciences across 50 filings.
- Castle Creek Biosciences has filed 4 Form Ds with the SEC since 2021, most recently Feb 2025 ($75.0M sold to 30 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$223per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Castle Creek Biosciences
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Castle Creek Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest May 20262 SEC-registered funds reported 50 fair-value marks on Castle Creek Biosciences between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
4 roundsAbout Castle Creek Biosciences
Developer of a fibroblast based therepy designed to treat rare and serious genetic diseases. The company extracts fibroblast cells from a patient's skin to create localized cell and gene therapies that are tailored to individual biology, enabling physicians to offer personalized treatment options for underserved disorders with limited therapeutic alternatives.
- Sector
- Healthcare
- HQ
- Exton, PA, United States
- Founded
- 2015
- Employees
- 36
- Website
- castlecreekbio.com/
- Ownership
- Privately Held (backing)